Abstract 1365P
Background
Lung cancer is the leading cause of cancer deaths globally, with an average age at diagnosis of 70. Lung cancer and Alzheimer Disease Related Dementia (ADRD) occur frequently in older adults, but little is known about the impact on care or treatment. The purpose of this study was to characterize patterns of treatment and healthcare utilization among older adults diagnosed with lung cancer with and without concomitant dementia.
Methods
We used the Surveillance Epidemiology and End Result (SEER) registry linked with Medicare data to conduct a retrospective cohort study of adults ≥66 years diagnosed with non-small cell lung cancer (NSCLC) between 2011 and 2017. We estimated dementia prevalence using the Bynum 1-year algorithm and evaluated use of cancer surgery, chemotherapy, immunotherapy, radiation, and healthcare utilization for 1-year following diagnosis or until death. We used t-tests and chi-square tests to evaluate significant differences between individuals with and without ADRD in stages I-III and IV.
Results
Stage IV NSCLC was more prevalent (n=46,987) than stage I-III (n= 40,084), but both groups had similar ADRD prevalence rates (3.43% stage I-III, 3.25% stage IV). Regardless of cancer stage, ADRD cohorts had higher prevalence of Spanish, Hispanic, or Latino and Black or African American individuals. Older adults with ADRD were significantly less likely to receive systemic drug therapy, especially for those with Stage IV cancer. Stage I-III (ADRD 12.14; non ADRD 29.65) X 2 (1, N=40,084) =197.79, p<.01 and Stage IV (ADRD 14.95; non ADRD 40.63) X 2= (1, N=46,987) = 405.97, p<.01. Overall, individuals with ADRD had significantly higher health care usage for both groups except for ICU admissions (stage I-III -0.07 [-0.12, -0.03]; Stage IV -0.03 [-0.07, -0.02]).
Conclusions
Our results suggest that individuals with ADRD diagnosed with both early stage and later stage NSCLC receive less cancer treatment in the form of drug therapy. This may be due to clinician bias regarding older adults with ADRD, or reflect caregiver or patient priorities, e.g., quality of life valued over intervention for longer survival. Given that one in three older adults dies with dementia, this is an important area for further research.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Global Brain Health Institute.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1383P - Distribution of actionable genetic variants in different sample types of Chinese NSCLC: A large real-world data based study
Presenter: Dongmei Lin
Session: Poster session 06
1384P - Efficacy of cemiplimab as monotherapy or in combination with chemotherapy in Japanese patients with advanced non-small cell lung cancer (aNSCLC)
Presenter: Yuki Sato
Session: Poster session 06
1385P - Uncovering resistance mechanisms and vulnerabilities of KEAP1 mutated lung adenocarcinoma
Presenter: Mariana Mancini
Session: Poster session 06
1386P - Prognostic value of EGFR A859S alteration in advanced NSCLC patients treated with third-generation EGFR-TKI
Presenter: Wei Xin Zhao
Session: Poster session 06
1387P - Real-world data, tolerability and clinical outcomes in patients with advanced NSCLC treated with sotorasib in the UK
Presenter: Rubab Batool
Session: Poster session 06
1388P - Molecular testing in patients with advanced NSCLC from 2016-23 (Prospective German Registry CRISP, AIO-TRK-0315)
Presenter: Frank Griesinger
Session: Poster session 06
Resources:
Abstract
1389P - Safety and effectiveness of immune checkpoint inhibitor therapy in patients with lung cancer and pre-existing autoimmune disease
Presenter: Siddhartha Goutam
Session: Poster session 06
1390P - Clinical characteristics and treatment outcomes of patients with thoracic SMARCA4-deficient tumour
Presenter: Inès Duparc
Session: Poster session 06